Prehospital recognition and antibiotics for 999 patients with sepsis: protocol for a feasibility study by Alison, Porter et al.
 Cronfa -  Swansea University Open Access Repository
   
_____________________________________________________________
   
This is an author produced version of a paper published in:
Pilot and Feasibility Studies
                                    
   
Cronfa URL for this paper:
http://cronfa.swan.ac.uk/Record/cronfa46154
_____________________________________________________________
 
Paper:
Moore, C., Bulger, J., Morgan, M., Driscoll, T., Porter, A., Islam, S., Smyth, M., Perkins, G., Sewell, B.,  et. al. (2018).
Prehospital recognition and antibiotics for 999 patients with sepsis: protocol for a feasibility study. Pilot and Feasibility
Studies, 4(1)
http://dx.doi.org/10.1186/s40814-018-0258-8
 
 
 
 
 
 
Released under the terms of a Creative Commons Attribution License (CC-BY). 
 
_____________________________________________________________
  
This item is brought to you by Swansea University. Any person downloading material is agreeing to abide by the terms
of the repository licence. Copies of full text items may be used or reproduced in any format or medium, without prior
permission for personal research or study, educational or non-commercial purposes only. The copyright for any work
remains with the original author unless otherwise specified. The full-text must not be sold in any format or medium
without the formal permission of the copyright holder.
 
Permission for multiple reproductions should be obtained from the original author.
 
Authors are personally responsible for adhering to copyright and publisher restrictions when uploading content to the
repository.
 
http://www.swansea.ac.uk/library/researchsupport/ris-support/ 
 STUDY PROTOCOL Open Access
Prehospital recognition and antibiotics
for 999 patients with sepsis: protocol for
a feasibility study
Chris Moore1, Jenna Bulger2*, Matt Morgan3, Timothy Driscoll1, Alison Porter1, Saiful Islam1, Mike Smyth4,
Gavin Perkins4, Bernadette Sewell2, Timothy Rainer3, Prabath Nanayakkara5, Chukwudi Okolie2, Susan Allen3,
Greg Fegan2, Jan Davies6, Theresa Foster7, Nick Francis3, Fang Gao Smith8, Gemma Ellis3, Tracy Shanahan3,
Robin Howe9 and Helen Snooks2
Abstract
Background: Sepsis is a common condition which kills between 36,000 and 64,000 people every year in the UK.
Early recognition and management of sepsis has been shown to reduce mortality and improve the health and
well-being of people with sepsis. Paramedics frequently come into contact with patients with sepsis and are well
placed to provide early diagnosis and treatment.
We aim to determine the feasibility of undertaking a fully powered randomised controlled trial (RCT) to test the
clinical and cost-effectiveness of paramedics obtaining blood cultures from and administering IV antibiotics to
patients with sepsis, so we can make a decision about whether to proceed to a fully powered randomised
controlled trial, which will answer questions regarding safety and effectiveness for patients and benefit to the
National Health Service (NHS).
Methods/design: This is an individually randomised, two-arm feasibility study for a randomised controlled trial with
a 1:1 ratio. Sixty paramedics will receive training to assist them to recognise sepsis using a screening tool, obtain
blood cultures, and provide IV antibiotics. If sepsis is suspected, paramedics will randomly allocate patients to
intervention or usual care using their next sequential individually issued scratch card. Patients will be followed up at
90 days using linked anonymised data to capture length of hospital admission and mortality. We will also collect
self-reported health-related quality of life (using SF-12) at this time. We will interview ten patients by telephone and
hold a focus group with paramedics, to find out what they think about the intervention.
Discussion: At the end of this study, we will make a recommendation about whether a full randomised controlled
trial of paramedics obtaining blood cultures and administering IV antibiotics for sepsis is warranted, and if so, we
will develop a proposal for research funding in order to take the work forward.
Trial registration: ISRCTN, ISRCTN36856873
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Background
Sepsis is caused by the body’s dysregulated immune re-
sponse to an infection. It is a time-critical condition
which can rapidly lead to multi-organ failure and death
[1, 2]. Sepsis has a mortality rate as high as 35%, killing
between 36,000 and 64,000 people in the UK every year
[3]. More people in the UK die from sepsis than lung
cancer or breast and bowel cancer combined [4]. There
is evidence to suggest that early diagnosis of sepsis and
early administration of intravenous (IV) antibiotics can
reduce morbidity and mortality from sepsis [4–6]. The
prehospital phase of emergency medical care provides
the earliest opportunity for identification of sepsis and
delivery of immediate life-saving treatment for patients.
It is known that recognition of sepsis in the ambulance
can speed up care in the emergency department (ED)
and that these patients get the required diagnostics and
treatment sooner [7, 8]. Emergency medical services
(EMS) personnel may, therefore, play a major role in the
identification, pre-alert, and initial management of sep-
sis. Traditionally, EMS training has focused on assessing
and managing ‘barn door’ presentations such as chest
pain and ST segment elevation myocardial infarction,
stroke and transient ischaemic attack, and acute trauma.
To date there has been little focus on the acute assess-
ment and management of sepsis, though the National
Early Warning Score (NEWS) system is now used by
some EMS providers. Approximately 50% of patients
with sepsis in the ED arrive by ambulance [9, 10], with
an average prehospital care time of 45 min [11]. This
suggests an important window of opportunity for early
recognition and care of sepsis before hospital arrival.
Despite the importance of this condition and the need
for rapid emergency care, the evidence base to support
the use of prehospital antibiotics is weak [12, 13], with
currently no well-defined prehospital protocol for sep-
sis in the UK. EMS personnel already play a key role
in providing early recognition, initial treatment, and
rapid transport for patients with other time-critical
conditions; expanding the evidence base on the pre-
hospital management of sepsis is crucial to determin-
ing whether earlier identification and management in
the prehospital setting could improve health outcomes
and speed up care at the ED.
Feasibility study aim
The aim of this study is to determine the feasibility of
undertaking a fully powered randomised controlled trial
(RCT) to test the clinical and cost-effectiveness of para-
medics obtaining blood cultures from and administering
IV antibiotics to patients with sepsis.
Feasibility study objectives
1. Intervention development:
To work with clinicians, paramedics, pharmacists, and
service users to develop a prehospital intervention for
sepsis, comprising:
(a)A protocol for collection of blood cultures,
administration of antibiotics, and handover
(b)Training for paramedics to deliver the agreed
protocol
2. Intervention feasibility:
(a)To assess paramedic uptake and satisfaction with the
training package
(b)To assess paramedic compliance with treatment
protocol
(c)To determine safety and acceptability of the
intervention to patients and paramedics
3. RCT feasibility:
(a)To develop and test trial recruitment, randomisation,
and data collection processes
(b)To assess sample size requirements and attrition
rates
(c)To determine availability of outcome data
(d)To clarify primary and secondary outcome measures
4. Full trial planning:
(a)To assess our findings against our progression criteria
and, if met,
(b)Draft a full trial application to the HTA Research
Programme
Progression criteria
We will assess whether or not to proceed to a full multi-
site RCT based on the following progression criteria, all
of which should be met within reasonable limits (for ex-
ample, if the progression criterion is within 5% of the
target, we will review reasons for this and consider mod-
ifications to protocol; if within 10%, we will critically re-
view reasons for this and assess whether major changes
to protocol are likely to improve the issue; if more than
10%, we will not progress. The limits for each progres-
sion criterion will be stated in our statistical analysis
plan; arbitrary limits of 5 and 10% have been suggested
here for convenience).
Intervention feasibility
1. Compliance with protocol by paramedics—no less
than 80% of patients recognised as eligible patients
by study paramedics are randomised
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2. Acceptability of intervention to patients—mean
patient satisfaction in intervention group is not less
than 80% of patient satisfaction in the control group
3. Safety—number of patients who experience adverse
events has a difference of less than 10% between trial
arms
4. Recognition of sepsis (success of training)
(a) At least 50% of patients with sepsis who are
attended by study paramedics are recognised as
eligible for the study.
(b) At least 70% of randomised patients are
diagnosed with sepsis in hospital.
RCT feasibility
5. Acceptability of RCT to paramedics—at least 60%
of eligible paramedics agree to take part in the study
6. Acceptability of RCT to patients—dissent to take
part in the study is 30% or less
7. Retrieval of outcomes—follow-up data for primary
outcome suitable for fully powered trial can be
collected for 70% or more of patients
8. Equipoise—findings indicate that we remain in
equipoise about the effectiveness of paramedic
obtained blood cultures and prehospital antibiotics
for sepsis.
9. Recruitment—recruitment target met to at least 80%
Design
Individually randomised (1:1) feasibility trial. The unit of
randomisation is the individual patient.
Setting
The prehospital environment in the urban geographic
area serving UHW, Cardiff. Paramedics based at all
ambulance stations and fire stations in the Cardiff
and Vale of Glamorgan localities of the Welsh Ambu-
lance Services NHS Trust (WAST) will be invited to
take part in PhRASe.
Participants
Patient eligibility
Inclusion criteria:
• Adult patients (18 years or older) with ‘Red Flag’
Sepsis (as defined by the Screening Tool seen in Fig. 1)
• Attended by study paramedics
• Will be conveyed to UHW
Exclusion criteria:
• Pregnancy (known or suspected)
• Known history of allergy to antibiotics
Consent
It is acknowledged and accepted that it is not ethically
appropriate to consent patients to research within the
context of a medical emergency [14]. We have an ex-
perience of carrying out randomised trials in emer-
gency care through the SAFER programme and TIER
and RAPID feasibility trials [15, 16] and have success-
fully gained ethical, research, and information govern-
ance approvals to inform people of their inclusion in
research following their attendance by emergency am-
bulance. At the time of paramedic attendance, there-
fore, patients will only be asked to provide consent to
have blood cultures collected and receive antibiotics,
should they be randomly allocated to the intervention
arm. Verbal consent for these procedures will be
taken by the paramedics, as would be normally taken
for cannulation or venepuncture.
We will provide patients who have been recruited to
the study with a Patient Information Sheet, which in-
cludes a ‘Participant Dissent Form’. This will be sent at
90 days (30 days for those recruited in the last two
months of the study) after the patient’s 999 call. This
gives the patient the option to:
1. Decline to receive any further correspondence from
the study
2. Have all of their records withdrawn from the study
Any patients who dissent at this point are taken
out of all further involvement, including anonymised
follow-up. We have included service users in discus-
sions about this approach which minimises intrusion
and possible distress, whilst allowing the opportunity
for informed involvement in patient follow-up
through qualitative methods. The patient question-
naire sent at 90 days will include a question of
whether the patient is willing to take part in an inter-
view about their experiences of 999 care for sepsis.
The Paramedic Research Support Officer (PRSO) will
check the mortality status of patients before a Patient
Information Sheet and questionnaire is sent to min-
imise distress to bereaved relatives. This means that
patients who have deceased are included in our ana-
lysis as there is unfortunately no opportunity to give
them the option to dissent. The Patient Information
Sheet for the study can be seen in Additional file 1.
Sample size
Paramedics will recruit patients over a 6 month period.
Based on data regarding throughput of sepsis cases in
ED, we estimate a recruitment of approximately 100–
150 patients. In this feasibility study, we will not be
attempting to detect a clinically significant difference be-
tween the intervention and control groups in terms of
outcomes, but rather to collect enough data to assess
our methods against our progression criteria.
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Methods
Usual care
At present, when a paramedic suspects a patient has
sepsis, they will provide the patient with oxygen to
maintain saturations over 94% (88% if the patient has
chronic obstructive pulmonary disease) and give 250 ml
boluses of 0.9% sodium chloride (up to 2000 ml if the
patient is hypotensive, e.g. systolic blood pressure less
than 100 mmHg, but clinical judgement can be used,
taking into account the patient’s age and other clinical
parameters). In addition, they will pre-alert the receiving
hospital so that the patient can be taken directly to a
resuscitation bay. During PhRASe, this care will con-
tinue to be given to both groups, with additional care
given to patients in the intervention arm.
Intervention development
A clinical intervention development group comprising
paramedics, doctors, nurses, and pharmacists from pre-
hospital care, emergency medicine, critical care, and
microbiology met to define the exact treatment protocol
and training methods for paramedics to follow early in
the study period. They used clinical and local knowledge,
research literature, and guidelines from the Joint Royal
Fig. 1 Screening tool
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Colleges Ambulance Liaison Committee (JRCALC) and
UHW. Based on advice from Public Health Wales, cefo-
taxime will be the antibiotic administered to patients in
this feasibility study. The Screening Tool and Study
Flowchart can be seen in Fig. 1; the screening tool is an
adaptation of The UK Sepsis Trust’s Prehospital Sepsis
Screening and Action Tool [17]. We decided only to in-
clude patients with Red Flag Sepsis in this feasibility
study so that we did not broaden the use of antibiotics
unnecessarily, in line with antimicrobial stewardship.
Paramedic recruitment and training
We aim to recruit at least 60 of approximately 100 para-
medics working in all ambulance stations and fire sta-
tions in the Cardiff and Vale of Glamorgan localities of
WAST on a volunteer basis.
All study paramedics will be trained to recognise sep-
sis using the PhRASe screening tool, as well as to collect
blood cultures and prepare and administer IV antibiotics.
The training given to the paramedics will include the
need to identify whether the patient has a known allergy
to antibiotics, prior to administration, and the use of
Aseptic Non Touch Technique (ANTT); although the
collection of blood cultures within the hospital setting is
routine, the collection of blood cultures in prehospital
care is not a routinely practised skill for EMS staff and
requires sound knowledge and practice of aseptic tech-
nique. The use of antibiotics (cefotaxime) will be sup-
ported by a patient group direction (PGD), which will
allow the paramedics to administer a drug which is
not routinely available to them under existing legal
exemptions. Training will be delivered using formal
group teaching sessions, e-learning, and one-to-one
practical sessions.
Randomisation
A randomisation schedule with a 1:1 ratio of ‘interven-
tion’ or ‘control’ and stratified by paramedic will be pro-
duced by an independent statistician. Scratch cards will
be produced to conceal the allocation, and a set of
scratch cards will be issued to each study paramedic and
be kept on their person in the pocket of their uniform
during each working shift. When the study paramedic
identifies an eligible patient, they will use their next se-
quential individually issued scratch card out of the sight
of the patient. The unique number shown on the scratch
card will become the patient’s study ID. This means the
paramedic is always able to recruit a patient to the study
and does not rely on having an Internet connection, a
telephone signal, or a requirement to return to the am-
bulance to access the trial pack, to undertake the ran-
domisation. The paramedic will retain the scratch card
in order to store it with the randomisation log at the
nurses’ station in UHW Resus, so that the PRSO can
monitor randomisation.
Blinding
Due to the nature of the intervention, the outcome of
randomisation will not be blinded to the paramedics or
patients. As data will be collected by the PRSO and han-
dled by the data manager, they will also not be blinded
to the allocation. The trial statistician will remain
blinded to the allocation when conducting analysis.
Outcomes
Part of the purpose of this study is to help us to define
the primary outcome for a fully powered trial. Those to
be tested include:
1. Routinely collected anonymised data
(a)Mortality
(b)Length of hospital stay
2. Patient reported (at 90 days)
(a)Health-related quality of life using SF-12
Secondary outcomes to be tested include:
1. Routinely collected anonymised data
(a)Length of intensive care unit stay
(b)Time from 999 call to administration of antibiotic by
paramedic/in hospital
(c)Job cycle time, on-scene time
(d)Hospital diagnosis of sepsis or other condition
(e) Intervention cost
(f ) Contamination of blood cultures
2. Patient reported (at 90 days)
(a)Patient satisfaction with care received by paramedics
using quality of care monitor
Data collection
Missed recruitments
There are two ways in which patients with sepsis who
are attended by study paramedics may not be recruited:
1. The study paramedic does not recognise that the
patient has sepsis
2. The study paramedic recognises that the patient has
sepsis but does not randomise them
As part of this feasibility study, we will monitor for
missed recruitments so that we can determine whether
paramedics are able to accurately recognise patients with
sepsis, whether paramedics are compliant with the
protocol, and how many patients could not be rando-
mised due to the exclusion criteria. The PRSO will
Moore et al. Pilot and Feasibility Studies  (2018) 4:64 Page 5 of 8
compare recruited patients to all the patients admitted
to UHW by study paramedics with sepsis. The PRSO
will be able to discuss with individual paramedics any
problems or concerns that they may have.
Quantitative
Data relating to clinical outcomes and hospital diagnosis
will be obtained from the Secure Anonymised Informa-
tion Linkage (SAIL) databank. The SF-12 and Quality of
Care monitoring forms will be sent out to participants at
90 days (30 days for participants recruited in the last
2 months of the study) along with the Patient Dissent
Forms to be returned directly to the research team at
SU for data entry. Routine data will be used for para-
medic call out information and will be collated by the
PRSO. The PRSO will collect basic demographic details,
i.e. age and gender, so that we can see whether partici-
pants’ baseline characteristics were similar between trial
arms (indicating that randomisation was successful), as
well as whether all patients who are allocated to inter-
vention have both blood cultures taken and IV antibi-
otics given (as the paramedics may be unable to obtain
blood cultures or give IV antibiotics in some cases). This
information will be collected from patient’s WAST Pa-
tient Clinical Record.
Qualitative
Interview respondents will be sampled purposively [18]
in a way previously used for Air Quality Alert scheme
participants (findings not yet published). We will aim to
explore with patients their experience of receiving the
intervention and experience of recovery including overall
quality of life. We will devise a semi-structured interview
schedule, which will give the opportunity for patients to
expand on information given on questionnaire forms
about quality of life as well as asking for their views of
the intervention through questions and prompts. We
will sample 10 patients, selected purposively from those
who receive IV antibiotics, to include a range of:
 Age
 Gender
 Time and day of attendance
 Study paramedic who assessed the patient
Interviews will be conducted over the telephone, as
this is felt to be the most convenient and least intrusive
to respondents.
Approximately ten paramedics will be invited to par-
ticipate in focus group(s) to explore their views on the
intervention. We will devise a topic guide consisting of a
series of questions and prompts about whether they con-
sider prehospital IV antibiotics an acceptable method of
providing treatment for patients with sepsis compared
with usual treatment and their experience of delivering
the intervention. The focus group(s) will be conducted
towards the end of patient recruitment and will be re-
corded and transcribed. We will also collect any com-
plaints to WAST or CVUHB relating to the trial, should
any be received.
All qualitative data will be recorded (with explicit per-
mission to do so) and transcribed verbatim.
Data handling
Study data will be collected and managed using REDCap
(Research Electronic Data Capture) electronic data cap-
ture tools hosted at SU; the PRSO and project adminis-
trator will input the data into REDCap [19]. REDCap is
a secure, web-based application designed to support data
capture for research studies, providing (1) an intuitive
interface for validated data entry, (2) audit trails for
tracking data manipulation and export procedures, (3)
automated export procedures for seamless data down-
loads to common statistical packages, and (4) procedures
for importing data from external sources.
Data will be monitored on an on-going basis for com-
pleteness and precision by the data manager and
through source data verification; it will be frozen as soon
as possible thereafter to prevent changes made in error.
All reasonable effort will be made to minimise missing
data, and we shall adopt a consistent approach to miss-
ing data at the analysis stage (except where individual
variables require otherwise).
Identifiable information will be seen only by the quali-
tative researcher in SU in order to contact them to invite
them to take part in an interview (if the patient has
stated they are happy to be contacted for this purpose).
Qualitative data will be anonymously stored on
password-protected computers at SU. Identifiable infor-
mation will be removed from interview transcripts and
stored separately and securely.
The PRSO will hold identifiable data securely only
to enable us to collect anonymised outcomes for
them via SAIL.
Analysis
The analysis of quantitative data will mainly be descrip-
tive. We will report baseline characteristics, the number
of participants randomised to each arm, and the number
who received the treatment allocated. Continuous out-
comes (e.g. SF-12 Score; length of stay) will be analysed
using t tests, or non-parametric equivalents, and we will
report mean and standard deviation, or median and
interquartile range, along with 95% confidence intervals.
Categorical outcomes (e.g. mortality, presence of sepsis)
will be analysed using chi-squared tests, and we will re-
port raw counts, proportions (n, %), and 95% confidence
intervals. We will conduct exploratory analysis only of
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our potential primary outcomes to determine whether
we have met progression criterion 8 (whether we remain
in equipoise), as well as to help to decide which is the
most appropriate for use as the primary outcome in a
fully powered trial. We will report against each of our
progression criteria to determine whether we should
seek further funding for a fully powered trial and provide
the necessary estimates for performing the power calcu-
lation for the potential fully powered trial, if warranted.
We will perform analysis using SPSS and report results
using the relevant CONSORT checklists [20, 21].
We will use a thematic analysis approach for the quali-
tative data, analysing the patient and paramedic datasets
separately, with input from at least two members of the
research team to each analysis. We will look for
consistency of viewpoint among respondents and will
explore any deviations from the predominant view and
possible reasons for this.
As this is a feasibility study, no formal health eco-
nomic analysis will be undertaken. Health economics
will focus on establishing the main cost drivers by esti-
mating the intervention implementation cost, necessary
parameters required (including measures used to collect
costs/outcomes), and suitable framework to undertake a
full cost-effectiveness analysis in a future trial. We will
examine the feasibility of collecting data on outcomes
and resource use by examining the completeness and re-
sponse rate from the measures and consider solutions to
collecting data in a full trial. We will investigate the de-
sign options of a future economic evaluation required
including capturing longer-term horizons, e.g. any mod-
elling that would be required alongside a future in-trial
analysis of cost-effectiveness.
Safety reporting
In the PhRASe feasibility study, safety reporting has two
functions:
1. To monitor the safety of patients enrolled into the
two arms of the trial;
2. To develop robust and practical safety reporting
procedures for use in a fully powered multi-centred trial.
A principle of adverse event reporting is that safety
should be monitored in both arms of the trial. Harms
that occur after the patient has arrived at hospital could
be a direct or indirect result of the treatment received in
the prehospital environment. In some cases, we will be
able to directly attribute the adverse event to the admin-
istration of antibiotics in the prehospital environment,
but this will not be possible in all cases. We will monitor
for the following serious adverse events (SAEs) in all pa-
tients up to 1 week:
• Anaphylaxis
• C. difficile infection
• Extravasation at the site administration of antibiotics
• Infection/cellulitis at the site of blood culture collec-
tion/administration of antibiotics
• Vascular damage at the site of blood culture collec-
tion/administration of antibiotics
SAE monitoring will be conducted by the PRSO so
that the research team do not see any identifiable infor-
mation. The PRSO will alert the Principal Investigator at
UHW of all SAEs so that they can be assessed for ser-
iousness and relatedness to the intervention. The Trial
Manager will report any Suspected Unexpected Serious
Adverse Reactions to the Research Ethics Committee,
Sponsor, and the TSC’s Chair and Clinicians within 24 h
of receiving notification of them. The rest of the TSC
will be informed within 1 week, via the Chair.
We expect to capture harms beyond the 1-week
follow-up period for SAEs through the outcomes for the
trial, i.e. length of stay and mortality. Deaths and ICU
admissions will be reported to the Trial Management
Group on a three-monthly basis to ensure there are no
safety concerns. For safety reporting purposes, this will
be checked through routine records—this information
will also be captured using the Secure Anonymised In-
formation Linkage Databank, but due to a time lag in
this information being available, we must also use alter-
native sources for interim reporting.
Discussion
Service users have been involved in developing the initial
research idea and preparing an application for funding
for PhRASe, as well as in decision-making regarding all
documentation for PhRASe, particularly the information
sheet for patients. Service users will sit on the Trial
Management Group and Trial Steering Committee
throughout the trial to ensure that patient’s views are
considered equally, as well as take part in analysis and
dissemination of our findings.
Interviews and focus groups will be used as a source
of information to develop the main trial (if warranted),
for example, if suggestions are made as to how to im-
prove the trial protocol.
It should be noted that PhRASe is not a Clinical Trial
of Investigational Medicinal Product (CTIMP), as we are
not testing the efficacy of antibiotics. Rather, we are test-
ing the prehospital collection of blood cultures and ad-
ministration of antibiotics in a technique which has not
been previously tested by paramedics or in the prehospi-
tal setting.
We are aware that the nurses’ station in UHW resus,
where the randomisation log will be kept during patient
recruitment, is a very busy environment. We have taken
steps to ensure that the log is not lost—including attach-
ing it to the desk with string and placing a Bluetooth
tracker on.
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